As­traZeneca inks $247M deal with gen­er­a­tive AI shop Ab­sci to de­vel­op an­ti­body drug for can­cer

As­traZeneca is join­ing forces with Ab­sci in a deal worth up to $247 mil­lion fo­cused on us­ing AI to con­duct large-scale pro­tein analy­sis to de­sign a new an­ti­body-based drug can­di­date for can­cer.

The $247 mil­lion to­tal com­pris­es an undis­closed up­front pay­ment to Ab­sci, as well as fur­ther fund­ing and mile­stone pay­ments. Ab­sci could al­so get roy­al­ties on prod­uct sales. The Fi­nan­cial Times re­port­ed the news on Sun­day. As­traZeneca and Ab­sci did not im­me­di­ate­ly re­spond to an End­points News re­quest for com­ment, but Ab­sci con­firmed the news in a press re­lease on Mon­day morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER